SCHEMBL7651149

SCHEMBL7651149

Cc1nc2ccc(C(=O)NS(=O)(=O)/C=C/c3ccccc3)cc2n1Cc1ccc(/C=C/c2ccccc2)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.59
HDAC1 Q13547 4/20 0.47
HDAC6 Q9UBN7 4/20 0.47
HDAC2 Q92769 3/20 0.47
HDAC11 Q96DB2 3/20 0.47
HDAC8 Q9BY41 3/20 0.47
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
APP P05067 1/20 0.40
RORC P51449 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7651157 1.00 PPARG (0.59) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL6134137 0.93 PPARG (0.68) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL6134141 0.93 PPARG (0.68) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL7659181 0.93 PPARG (0.59) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL7659185 0.93 PPARG (0.59) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL6135126 0.92 PPARG (0.57) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL6135122 0.92 PPARG (0.57) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL7649095 0.92 PPARG (0.57) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL7649100 0.92 PPARG (0.57) PPARGHDAC1HDAC6HDAC2HDAC11
SCHEMBL7654068 0.90 PPARG (0.55) PPARGHDAC1HDAC6HDAC2HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed